VENEZE Peptide Factor Hair Serum Compared With Topical 2% Minoxidil for Androgenetic Alopecia

Inclusion Criteria:

• Male or female participants aged ≥18 years.

• Diagnosed with androgenetic alopecia (AGA): Norwood-Hamilton classification III-V inmales or Ludwig classification I-II in females.

• Able to read and write for completion of study questionnaires (e.g., Patient GlobalAssessment, Hair Growth Questionnaire).

• Willing to comply with study procedures, including maintaining consistent hair colorand hairstyle throughout the study.

• Hair length in the non-balding area (vertex surrounding area) ≥2 cm at each visit.

• Able to attend all scheduled visits during the 24-week study period.

Exclusion Criteria:

• Presence of unstable or uncontrolled systemic diseases that may affect hair growthor loss within 6 months prior to screening (e.g., liver, renal, thyroid,cardiovascular, neurological diseases, diabetes, anemia).

• History of malignancy within the past 5 years, except adequately treated basal cellcarcinoma or squamous cell carcinoma.

• Psychiatric disorders or other conditions that may affect participant safety orcompliance.

• Pregnant or breastfeeding women.

Hair and scalp-related exclusions:

• Diffuse hair thinning involving the occipital area.

• Scalp conditions or diseases affecting hair growth (e.g., tinea infection, non-AGAhair loss, psoriasis, uncontrolled seborrheic dermatitis).

• History of hair transplantation at any time or hair extensions within 6 months priorto screening.

• Use of cosmetic products for hair loss concealment within 2 weeks prior toscreening.

• Use of light/laser therapy on the scalp within 3 months prior to screening.

• Use of supplements related to hair growth (e.g., zinc, biotin) within 3 months priorto screening.

• Use of hair products containing active ingredients (e.g., caffeine, peptides) within 3 months prior to screening.

• Hair procedures such as mesotherapy or stem cell injection within 3 months prior toscreening.

Medication-related exclusions:

• Known hypersensitivity to study-related products or ingredients.

• Use of dutasteride within 12 months prior to screening.

• Use of systemic cytotoxic agents.

• Use of systemic glucocorticoids within 3 months prior to screening (except inhaledor topical corticosteroids not applied to the scalp).

• Use within 6 months prior to screening of:

• Minoxidil (topical or oral)

• Finasteride (topical or oral)

• Anti-androgenic drugs (e.g., spironolactone, cyproterone acetate, flutamide,bicalutamide)

• Prostaglandin analogs applied to the scalp

• Estrogen or progesterone topical preparations

• Tamoxifen

• Drugs associated with hypertrichosis (e.g., cyclosporine, phenytoin)

• Drugs associated with hair loss (e.g., valproic acid)

• Participation in another clinical trial within 1 month prior to screening or duringthis study.